[Breast cancer].

By H. Iwase. Nihon rinsho. Japanese journal of clinical medicine, 2006

7,773 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/9bb005f04021f8efce2d593a15b53dd4fa087a6d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

Citations in the corpus

Breast cancer early detection: A phased approach to implementation (2020, background): “the curve on the high costs of treatment, and 2) support technical assistance and research.(59) It is worth mention-”
iArc monogrAphs on the evAluAtion oF cArcinogenic risks to humAns (2012, methodology): “A combined analysis of the cohorts of Danish and Swedish Thorotrast patients (Travis et al., 2003) showed statistically significant trends with a surrogate measure for cumulative radiation dose in the incidence of primary liver cancer and cancer of the gallbladder.”
Current and future burden of breast cancer: Global statistics for 2020 and 2040 (2022, background): “Established risk factors for breast cancer include early age at menarche, later age at menopause, advanced age at first birth, fewer number of children, less breastfeeding, menopausal hormonereplacement therapy, oral contraceptives, but also alcohol consumption, excess body weight, and physical inac”
Annual Report to the Nation on the Status of Cancer, 1975–2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)–Associated Cancers and HPV Vaccination Coverage Levels (2013, background): “In addition to reproductive factors and postmenopausal hormone replacement therapy, obesity after menopause, weight gain throughout life, and alcohol consumption are also known risk factors for breast cancer (65).”
Transfer learning based histopathologic image classification for breast cancer detection (2018, background): “BC begins with uncontrolled proliferation of cells in the milk glands and ducts that carry milk to nipple [1].”
ChIP‐Atlas: a data‐mining suite powered by full integration of public ChIP‐seq data (2018, background): “…(eQTLs), a user’s own ChIP-seq peak-call data, and evolutionarily accelerated regions [24 – 26] as well as genes whose expression levels are changed by drug exposure, aging, or cancer development [27 – 29] (see http://chip-atlas.org/publications for the full list of publications citing ChIP-Atlas).”
Risk Factors and Preventions of Breast Cancer (2017, background): “HER2 protein is an epidermal growth factor receptor (EGFR) of tyrosine kinase family and form heterodimers with other ligand-bound EGFR family members such as Her3 and Her4, thus to activate downstream signaling pathways [34].”
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries (2024, background): “45 Time trends in breast cancer incidence mainly reflect changes in these”
Major depression after breast cancer: a review of epidemiology and treatment. (2008, background): “Depression in women with breast cancer [84] and estrogen deficiency [85,86] have been associated with significant cognitive and functional impairment, with improvements in cognition associated with estrogen and/or antidepressant treatment [87,88].”
VARIOUS TYPES AND MANAGEMENT OF BREAST CANCER: AN OVERVIEW (2010, background): “lymph nodes are present with other symptoms such as bone pain (bone metastases), shortness of breath (lung metastases), drop in appetite (liver metastases), unintentional weight loss (liver metastases), headaches, neurological pain or weakness [25].”
Changes in Personal Values in Pandemic Times (2021, methodology): “Frequency and intensity of worry over the COVID-19 pandemic was measured at Times 4 and 5 with an adapted form of the McCaul Brief Worry Scale (McCaul et al., 1996).”
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 (2021, background): “Nearly all patients with invasive breast cancer are advised to receive adjuvant systemic therapy.(42) The threshold for initiation of treatment is very low, even among nodenegative cancers (Figure 5).”